¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Slow fetal growth, unspecified"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • fetal membrane
    žƸ·
  • fetal monitoring
    žư¨½Ã, žƸð´ÏÅ͸µ
  • fetal movement
    ŵ¿, žƿ
  • fetal period
    žƱâ
  • fetal phonocardiogram
    žƽÉÀ½µµ
  • fetal placenta
    žÆÅ¹Ý
  • fetal position
    ÅÂÀ§, žÆÀ§Ä¡
  • fetal respiration
    žÆÈ£Èí
  • fetal rest
    žÆÀÜ·ù¹°
  • fetal rickets
    žƱ¸·çº´
  • fetal spine
    žÆÃ´Ãß
  • fetal surface
    žÆ(ÂÊ)¸é
  • fetal syphilis
    žƸŵ¶
  • fetal tachycardia
    žƺü¸¥¸Æ, žƺó¸Æ
  • persistent fetal hemoglobin
    Áö¼ÓžÆÇ÷»ö¼Ò
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • fetal bovine serum
    ¼ÒžÆÇ÷û
  • fetal death rate
    žƻç¸Á·ü
  • fetal death ratio
    žƻç¸Áºñ
  • fetal distress syndrome
    žưíÅëÁõÈıº, žÆÀý¹Ú°¡»çÁõÈıº
  • fetal heart rate
    žƽɹڼö
  • fetal heart sound
    žƽÉÀåÀ½
  • persistent fetal hemoglobin
    Áö¼ÓžÆÇ÷»ö¼Ò
  • anchorage dependent growth
    ºÎÂøÁõ½Ä, ºÎÂø¹ßÀ°
  • anchorage independent growth
    ºñºÎÂøÁõ½Ä, ºñºÎÂø¹ßÀ°
  • apical growth
    ³¡¼ºÀå
  • appositional growth
    µ¡ºÙÀ̼ºÀå
  • asynchronous growth
    ºñµ¿Á¶Áõ½Ä
  • growth abnormality
    ¼ºÀåÀÌ»ó
  • growth acceleration
    ¼ºÀå°¡¼Ó
  • bacterial growth rate
    ¼¼±ÕÁõ½Ä·ü
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • apical growth
    Á¤´Ü¼ºÀå, ÷´Ü¼ºÀå, ³¡¼ºÀå
  • appositional growth
    µ¡ºÙÀ̼ºÀå
  • grain growth
    ÀÔÀÚÀÇ ¼ºÀå.
  • growth
    ¼ºÀå, Áõ½Ä
  • growth abnormality
    ¹ßÀ°ÀÌ»ó.
  • growth abnormality
    ¼ºÀåÀÌ»ó
  • growth acceleration
    ¼ºÀå<Áõ½Ä>°¡¼ÓµµÇö»ó.
  • growth chart
    ¼ºÀ嵵ǥ(ËÛËöËÀ̰).
  • growth chart
    ¼ºÀ嵵ǥ(à÷íþÓñøú).
  • growth cone
    ¼ºÀå¿ø»Ô
  • growth constant
    ¼ºÀå»ó¼ö(¡­ßÈâ¦).
  • growth constant
    Áõ½Ä»ó¼ö
  • growth constant
    ¼ºÀå»ó¼ö(ÊÙË×Ëà).
  • growth curvature
    ¼ºÀå°î¼±(ÊÙË­ËÛ).
  • growth curvature
    ¼ºÀå°î¼±(¡­ÍØàÊ).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • early fetal death
    Á¶±âžƻç¸Á.
  • fetal
    žÆ(÷Ãä®)ÀÇ, ų»(÷ÃÒ®)ÀÇ.
  • fetal abortion
    žÆÀ¯»ê(¡­êüß§).
  • fetal alcohol syndrome
    žƼº ¾ËÄÚ¿Ã ÁõÈıº
  • fetal alcohol syndrome
    ÅÂ¾Æ ¾ËÄÚ¿Ã ÁõÈıº
  • fetal alcohol syndrome
    ÅÂ¾Æ ¾ËÄÚ¿Ã ÁõÈıº
  • fetal antigen
    ÅÂ¾Æ Ç׿ø(¡­ù÷ê«)
  • fetal appendage
    žƺμӹ°(¡­Ý¾áÕÚª).
  • fetal asphyxia
    žư¡»ç(¡­Ê£ÞÝ).
  • fetal blood
    žÆÇ÷(÷Ãä®úì).
  • fetal bovine serum
    ¿ìžÆÇ÷û, ¼ÒžÆÇ÷û
  • fetal breathing
    ÅÂ¾Æ È£Èí (÷Ãä® û¼ýå)
  • fetal calf serum
    ¿ìžÆÇ÷û, ¼ÒžÆÇ÷û
  • fetal circulation
    žƼøÈ¯(¡­âàü»), žÆÇ÷Çà(¡­úìú¼).
  • fetal cotyledon
    žÆÂÊŹݿ±
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
GF gastric fistula; gastric fluid; germ-free; glass factor; glomerular filtration; gluten-free; grandfa...
IUGR intrauterine growth rate; intrauterine growth retardation
PGH pituitary growth hormone; porcine growth hormone; prostaglandin H
SGF sarcoma growth factor; skeletal growth factor
JVP [POMD P 49 - 52]
  1) Jugular Vein Pressure
  2) Jugular Venous Pulse
...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
sEPSPs Slow excitatory postsynaptic potentials
SEM Slow eye movement
SO Slow oxidative
SPEV Slow phase eye velocity
SPV Slow phase velocity
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 10 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • proliferative growth
    Áõ½Ä¼º ¼ºÀå
  • retardation of growth
    ¼ºÀå Áö¿¬
  • somatic growth
    ½ÅüÇü ¼ºÀå, ü¼º ¼ºÀå
  • stationary phase of growth
    Áõ½Ä Á¤Áö±â
  • too much growth
    Áõ½Ä
  • total growth
    ÃÑ Áõ½Ä·®
  • tumor growth
    Á¾¾ç ¼ºÀå
  • uncontrolled destructive growth
    ºñÁ¶Àý¼º ÆÄ±«¼º ¼ºÀå
    ÀÎÀ§ÀûÀ¸·Î Á¶ÀÛÀÌ ¾ÈµÇ°í ÀÚ¶ó¸é¼­ ÆÄ±«Àû ¼ºÁúÀ» Áö´Ï´Â °Í.
  • vascular endothelial growth factor
    ¸Æ°ü ³»ÇǼ¼Æ÷ ¼ºÀå ÀÎÀÚ, Ç÷°ü ³»ÇǼ¼Æ÷ ¼ºÀå ÀÎÀÚ
  • vertical growth
    ¼öÁ÷ ¼ºÀå
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
growth cone collapse <cell biology> Loss of motile activity and cessation of advance by growth cones. There are now thought to be specific molecules that inhibit the motility of particular growth cones and are important in establishing correct pathways in developing nervous systems.
See: axon pathfinding.
(18 Nov 1997)
growth control <cell biology> When applied to cells usually means control of growth of the population, i.e. Of the rate of division rather than of the size of an individual cell.
(18 Nov 1997)
growth curve A graphic representation of the change in size of an individual or a population over a period of time.
(05 Mar 2000)
growth disorders Deviations from the average values for a specific age and sex in any or all of the following: height, weight, skeletal proportions, osseous development, or maturation of features. The concept includes both acceleration and retardation of growth.
(12 Dec 1998)
growth factor <biochemistry> A complex family of polypeptide hormones or biological factors that are produced by the body to control growth, division and maturation of blood cells by the bone marrow. They regulate the division and proliferation of cells and influence the growth rate of some cancers. These factors occur naturally but some can be synthesised using molecular biology techniques and are used clinically to stimulate normal white cell production following chemotherapy or bone marrow transplantation.
Examples include epidermal growth factor, platelet-derived growth factor, fibroblast growth factor. Insulin and somatomedin are also growth factors, the status of nerve growth factor is more uncertain. Perturbation of growth factor production or of the response to growth factor is important in neoplastic transformation.
(29 Sep 1997)
growth factors Proteins involved in cell differentiation and growth.Growth factors are essential to the normal cell cycle, and are thus vital elements in the life of animals from conception to death. Among other things, they mediate foetal development, play a role in maintenance and repair of tissues, stimulate production of blood cells, and, gone awry, participate in cancerous processes.
(05 Mar 2000)
growth hormone <endocrinology, hormone> Polypeptide (191 amino acids) produced by anterior pituitary that stimulates liver to produce somatomedins 1 & 2.
(13 Nov 1997)
growth hormone inhibiting hormone <protein> Gastrointestinal and hypothalmic peptide hormone (two forms: 14 and 28 residues), found in gastric mucosa, pancreatic islets, nerves of the gastrointestinal tract, in posterior pituitary and in the central nervous system. Inhibits gastric secretion and motility: in hypothalamus/pituitary inhibits somatotropin release.
(18 Nov 1997)
growth hormone-producing adenoma <tumour> An adenoma that produces the clinical picture of gigantism or acromegaly, although a third of the cells have no granules or are a mixture of acidophils and chromophobes; some tumours may secrete both growth hormone and prolactin; often an acidophil or eosinophil adenoma.
(05 Mar 2000)
growth hormone-regulating hormone <endocrinology> Hypothalamic hormones that induce (somatoliberin) or inhibit (somatostatin) the release of growth hormone (somatotropin).
(18 Nov 1997)
growth hormone-releasing factor <endocrinology> Peptide hormone related to the glucagon family, released from the pituitary, acts on the adenohypophysis to release growth hormone.
Synonym: somatoliberin, growth hormone-releasing factor.
(20 Sep 2002)
growth hormone-releasing hormone <endocrinology> Peptide hormone related to the glucagon family, released from the pituitary, acts on the adenohypophysis to release growth hormone.
Synonym: somatoliberin, growth hormone-releasing factor.
(20 Sep 2002)
growth hormone stimulation test <investigation> A test which measures the level of human growth hormone in response to the administration of the amino acid arginine. This test measures the ability of the pituitary gland to secrete growth hormone. Normal values in children are: 48 ng/ml. Normal values in men are 10 ng/ml. Normal values in women are 15 ng/ml. This test is used to evaluate infants with growth retardation. It may also be part of an evaluation for a pituitary tumour. Failure of arginine to raise growth hormone levels may indicate hypopituitarism or dwarfism.
(27 Sep 1997)
growth hormone suppression test <investigation> A test to determine if growth hormone is suppressed by hyperglycaemia. Growth hormone blood levels are determined sequentially after ingestion of a glucose-rich meal. If growth hormone levels remain elevated (after the glucose is given) then acromegaly or gigantism is suspected.
(27 Sep 1997)
growth inhibitors Endogenous or exogenous substances which inhibit the normal growth of human and animal cells or micro-organisms, as distinguished from those affecting plant growth (= plant growth regulators).
(12 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
ÅëÇÕ°Ë»ö ¿Ï·á